4-(4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl)morpholine | 340318-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl)morpholine
• 英文别名: 4-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]morpholine；4-[4-(2,5-dimethylpyrrol-1-yl)phenyl]morpholine
• CAS: 340318-88-9
• 化学式: C₁₆H₂₀N₂O
• mdl: MFCD02197477
• 分子量: 256.348
• InChiKey: CPFKQOVGMQLDDC-UHFFFAOYSA-N

物化性质

• 沸点：
  423.4±45.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  17.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl)morpholine 在 哌啶 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 (2Z,5Z)-3-cyclohexyl-5-((2,5-dimethyl-1-(4-morpholinophenyl)-1H-pyrrol-3-yl)methylene)-2-(phenylimino)thiazolidin-4-one
  参考文献：
  名称：

  Discovery and optimisation studies of antimalarial phenotypic hits

  摘要：

  There is an urgent need for the development of new antimalarial compounds. As a result of a phenotypic screen, several compounds with potent activity against the parasite Plasmodium falciparum were identified. Characterization of these compounds is discussed, along with approaches to optimise the physicochemical properties. The in vitro antimalarial activity of these compounds against P. falciparum K1 had EC50 values in the range of 0.09-29 mu M, and generally good selectivity (typically >100-fold) compared to a mammalian cell line (L6). One example showed no significant activity against a rodent model of malaria, and more work is needed to optimise these compounds. (C) 2015 The Authors. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2015.08.044
• 作为产物：
  描述：

  4-(4-吗啉基)苯胺 、 2,5-己二酮 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以37%的产率得到4-(4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl)morpholine
  参考文献：
  名称：

  具有激动剂/拮抗剂转换的新 FXR 配体化学型

  摘要：

  胆汁酸敏感转录因子法尼醇 X 受体 (FXR) 的治疗性调节是对抗肝脏和代谢疾病的一种有吸引力的策略。尽管有几种高效的 FXR 激动剂，但 FXR 调节剂的结构多样性是有限的，并且需要新的配体支架。在这里，我们报告了一种新的 FXR 调节剂化学型的结构-活性关系，其活性可以通过两个小的结构修饰在激动和拮抗之间进行调节。从弱 FXR/PPAR 激动剂开始，我们开发了具有纳摩尔到低微摩尔效力和结合亲和力的选择性 FXR 激活剂和拮抗剂。新的 FXR 配体化学型在天然细胞环境中调节 FXR 活性，具有良好的代谢稳定性，并且缺乏细胞毒性。

  DOI：

  10.1021/acsmedchemlett.0c00647

文献信息

• A New FXR Ligand Chemotype with Agonist/Antagonist Switch
  作者：Moritz Helmstädter、Jan Vietor、Jana Sommer、Simone Schierle、Sabine Willems、Astrid Kaiser、Jurema Schmidt、Daniel Merk

  DOI：10.1021/acsmedchemlett.0c00647

  日期：2021.2.11

  Starting from a weak FXR/PPAR agonist, we have developed selective FXR activators and antagonists with nanomolar to low-micromolar potencies and binding affinities. The new FXR ligand chemotype modulates the FXR activity in the native cellular setting, is endowed with favorable metabolic stability, and lacks cytotoxicity. It valuably expands the collection of FXR modulators as a new scaffold for FXR-targeted

  胆汁酸敏感转录因子法尼醇 X 受体 (FXR) 的治疗性调节是对抗肝脏和代谢疾病的一种有吸引力的策略。尽管有几种高效的 FXR 激动剂，但 FXR 调节剂的结构多样性是有限的，并且需要新的配体支架。在这里，我们报告了一种新的 FXR 调节剂化学型的结构-活性关系，其活性可以通过两个小的结构修饰在激动和拮抗之间进行调节。从弱 FXR/PPAR 激动剂开始，我们开发了具有纳摩尔到低微摩尔效力和结合亲和力的选择性 FXR 激活剂和拮抗剂。新的 FXR 配体化学型在天然细胞环境中调节 FXR 活性，具有良好的代谢稳定性，并且缺乏细胞毒性。
• Cascade Synthesis of Pyrroles from Nitroarenes with Benign Reductants Using a Heterogeneous Cobalt Catalyst
  作者：Pavel Ryabchuk、Thomas Leischner、Carsten Kreyenschulte、Anke Spannenberg、Kathrin Junge、Matthias Beller

  DOI：10.1002/anie.202007613

  日期：2020.10.12

  A bifunctional 3d‐metal catalyst for the cascade synthesis of diverse pyrroles from nitroarenes is presented. The optimal catalytic system Co/NGr‐C@SiO2‐L is obtained by pyrolysis of a cobalt‐impregnated composite followed by subsequent selective leaching. In the presence of this material, (transfer) hydrogenation of easily available nitroarenes and subsequent Paal–Knorr/Clauson‐Kass condensation provides

  提出了一种用于从硝基芳烃级联合成多种吡咯的双功能3d金属催化剂。最佳催化体系Co/NGr-C@SiO 2 -L是通过热解钴浸渍复合材料并随后进行选择性浸出而获得的。在这种材料的存在下，容易获得的硝基芳烃的（转移）氢化和随后的 Paal-Knorr/Clauson-Kass 缩合可使用二氢、甲酸或 CO/H 2 O混合物（WGSR条件）作为还原剂。除了有利的步骤经济性之外，这种简单的多米诺骨牌工艺不需要任何溶剂或外部助催化剂。该方法的一般合成效用在各种功能化底物上得到了证明，包括生物活性和药学相关化合物的制备，例如（+）-异沙莫坦。
• IMIDAZOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：TSD Life Sciences Co., Ltd.

  公开号：EP4023647A1

  公开（公告）日：2022-07-06

  The present invention relates to an imidazopyridine derivative and a pharmaceutical composition comprising same as an active ingredient and, more particularly, to an imidazopyridine derivative that inhibits protein kinase activity and as such, can be used for preventing or treating cancer, neurodegenerative disease, non-alcoholic fatty liver disease, influenza, etc., and a pharmaceutical composition comprising same as an active ingredient.

  本发明涉及一种咪唑吡啶衍生物及其作为活性成分的药物组合物，更具体地，涉及一种抑制蛋白激酶活性的咪唑吡啶衍生物，因此可用于预防或治疗癌症、神经退行性疾病、非酒精性脂肪肝病、流感等疾病，并包括该咪唑吡啶衍生物作为活性成分的药物组合物。
• Discovery and Structure–Activity Relationships of Pyrrolone Antimalarials
  作者：Dinakaran Murugesan、Alka Mital、Marcel Kaiser、David M. Shackleford、Julia Morizzi、Kasiram Katneni、Michael Campbell、Alan Hudson、Susan A. Charman、Clive Yeates、Ian H. Gilbert

  DOI：10.1021/jm400009c

  日期：2013.4.11

  In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 similar to 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.
• Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
  申请人：TSD LIFE SCIENCES CO., LTD.

  公开号：US20220396575A1

  公开（公告）日：2022-12-15

  The present invention relates to an imidazopyridine derivative and a pharmaceutical composition comprising same as an active ingredient and, more particularly, to an imidazopyridine derivative that inhibits protein kinase activity and as such, can be used for preventing or treating cancer, neurodegenerative disease, non-alcoholic fatty liver disease, influenza, etc., and a pharmaceutical composition comprising same as an active ingredient.